Answers are grounded in this paper and cite their sources.
Purpose: To evaluate the safety and efficacy of agonistic monoclonal antibody against roundabout receptor 4 (DS-7080a) in eyes with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) alone or in combination with ranibizumab. Design: This was a phase I dose escalation and expansion study registered on clinicaltrials.gov (NCT02530918) and conducted in 3 parts. Parts 1 (first phase of the study [P1]) and 2 (second phase of the study [P2]) involved dose escalation and expansion for patients with nAMD, while part 3 (third phase of the study [P3]) involved dose expansion only for DME subjects. Subjects: Patients with nAMD or DME. Methods: In P1, eligible patients were randomized into 3 sequential dose-level cohorts to establish a maximum tolerated dose for DS-7080a as 4.0 mg and assess its safety and tolerability. The study then proceeded to P2, where 27 nAMD subjects were randomized to one of the 3 treatment arms: DS-7080a, 4.0 mg only; ranibizumab, 0.5 mg only; or DS-7080a, 4.0 mg plus ranibizumab, 0.5 mg. In P3, 20 subjects with DME were randomized to one of the 2 arms: DS-7080a, 4.0 mg or ranibizumab, 0.3 mg injected thrice. The treatment period was 12 weeks. Main Outcome Outcomes: The primary endpoints were treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). The secondary endpoints were changes in central retinal thickness (central subfield thickness [CST]) and best-corrected visual acuity (BCVA). Results: A total of 56 patients were enrolled. Agonistic monoclonal antibody against Robo4, administered as monotherapy or in combination with ranibizumab, was generally well tolerated. Six drug-related TEAEs were observed, 4 of which were ocular events that led to treatment discontinuation. No drug-related SAEs or deaths occurred. As expected, ranibizumab was associated with improvements in BCVA and CST, whereas DS-7080a, alone or in combination, did not show clinically meaningful functional or anatomical benefit. Conclusions: Agonistic monoclonal antibody against Robo4 was generally well tolerated in eyes with nAMD and DME; however, drug-related TEAEs, including ocular events leading to discontinuation, were observed. In terms of efficacy outcomes, DS-7080a does not show BCVA improvement and CST decrease when administered alone or in conjunction with ranibizumab. These findings are inconsistent with nonclinical studies supporting DS-7080a as a therapeutic agent for nAMD and DME. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
No takes yet. Share an insight, caveat, or question.
Afridi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: